Ignacio
Melero Bermejo
Catedrático de Universidad
Publications by the researcher in collaboration with Ignacio Melero Bermejo (36)
2024
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
2023
-
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
Cell Reports Medicine, Vol. 4, Núm. 4
2022
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90
2021
-
Advances in immunotherapy for hepatocellular carcinoma
Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9
2020
-
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469
-
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncology
2018
-
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
-
Immunotherapy of hepatocellular carcinoma: Facts and hopes
Clinical Cancer Research, Vol. 24, Núm. 7, pp. 1518-1524
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502
2015
-
Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression
Gene Therapy, Vol. 22, Núm. 11, pp. 856-865
-
Immunological landscape and immunotherapy of hepatocellular carcinoma
Nature Reviews Gastroenterology and Hepatology, Vol. 12, Núm. 12, pp. 681-700
2014
-
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707
2013
-
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88
-
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model
Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162
2012
-
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
Journal of translational medicine, Vol. 10, pp. 122
2011
-
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142